Annetta Beauregard serves as Senior Vice President of Science and Regulatory Affairs at the Biotechnology Innovation Organization (BIO). In this role, she champions the evolution of U.S. Food and Drug Administration (FDA) policies and practices to ensure the United States remains a global leader in the development of innovative medicines. She collaborates with scientific, regulatory, and policy stakeholders across the U.S. and key international markets to advance efficient and predictable regulatory processes that bring innovation to patients.
Annetta joined BIO in 2025 following a 25-year career in global regulatory affairs at companies including Eli Lilly, Amgen, Merck Serono, Vertex, and Johnson & Johnson. She has led science and regulatory policy functions across the biopharmaceutical sector, with a passion for aligning science and policy enabling patient access to innovation. Her leadership has shaped numerous initiatives, including Prescription Drug User Fee Act (PDUFA) negotiations, contributions to Operation Warp Speed, and the development of hundreds of regulatory policies and guidance documents.
Annetta’s expertise spans regulatory strategy, project management, and operations across both emerging biotech and large pharmaceutical companies. She brings a comprehensive understanding of the drug development lifecycle and the unique challenges it presents at every stage.
A native of Indianapolis, Indiana, Annetta holds a B.S. and M.S. from the University of Indianapolis, where she currently serves on the Board of Trustees. She also holds an M.B.A. from Indiana University’s Kelley School of Business. She lives in Washington, D.C., with her husband and two daughters.